FONDAZIONE PENTA ETS

Their core work

Fondazione Penta is a Padova-based research foundation specializing in paediatric and maternal infectious disease research, with a strong focus on clinical trials and network coordination across Europe. They design and run multi-country clinical studies on childhood infections — from RSV and Zika to SARS-CoV-2 and antimicrobial resistance — and build the infrastructure (data platforms, biobanks, clinical practice networks) needed to conduct these studies at scale. Their work bridges epidemiology, drug development, and health economics to improve prevention and treatment of infectious diseases in vulnerable populations including neonates, children, and pregnant women.

What they specialise in

How they've shifted over time

Penta's early H2020 work (2016-2018) centered on paediatric disease fundamentals: Zika vertical transmission, RSV burden-of-disease studies, and building translational research infrastructure for children's medicines. From 2019 onward, their focus shifted decisively toward antimicrobial resistance, pandemic preparedness (SARS-CoV-2), and operational clinical research networks — moving from studying individual diseases to building resilient systems for responding to infectious disease threats broadly. The addition of health economics, federated learning, and implementation science in recent projects signals a maturation from pure clinical research toward real-world impact assessment and scalable intervention design.

Penta is evolving from a disease-specific paediatric research group into a broad infectious disease preparedness platform, increasingly integrating data science, health economics, and implementation research.

How they like to work

Penta operates as both a project leader and a trusted network partner — coordinating 3 of their 12 projects (including the massive c4c network at EUR 9.5M) while contributing specialist expertise to 9 others. With 185 unique consortium partners across 38 countries, they function as a high-connectivity hub rather than a closed-circle organization, making them easy to integrate into new consortia. Their consistent presence in large-scale coordination actions (ECRAID, ORCHESTRA) suggests they are experienced at managing multi-site clinical studies and comfortable in complex governance structures.

Penta has built one of the broadest networks in paediatric infectious disease research, with 185 unique partners spanning 38 countries — well beyond Europe into global health settings. Their REACH project specifically targets Russia and Eastern European partners, while ORCHESTRA and c4c connect institutions across the full EU landscape.

What sets them apart

Penta occupies a rare niche: they are one of very few European organizations that combine paediatric clinical trial coordination with infectious disease preparedness at scale. Their ability to coordinate the largest EU paediatric trials network (c4c, EUR 9.5M) while simultaneously contributing to rapid pandemic response efforts (RECoVER, ORCHESTRA) demonstrates operational flexibility that most research foundations lack. For consortium builders, Penta brings both the clinical network infrastructure and the regulatory know-how needed to run multi-country studies involving children and vulnerable populations — a combination that is genuinely difficult to find elsewhere.

Highlights from their portfolio

• c4c
  Largest project by far (EUR 9.5M), coordinated by Penta — the pan-European clinical trials network for children, representing their flagship infrastructure effort.
• ZIKAction
  Their first coordinated H2020 project, demonstrating early leadership in maternal-paediatric infection preparedness during the Zika crisis.
• NeoIPC
  Large-scale cluster randomised trial (EUR 2.9M) tackling resistant bacterial infections in neonatal ICUs — their most applied clinical intervention project.